CARDIFF ONCOLOGY INC (CRDF) Stock Price, Quote, News and Overview
NASDAQ:CRDF - Nasdaq - US14147L1089 - Common Stock - Currency: USD
CRDF Quote, Performance and Key Statistics
2.39
-0.02 (-0.83%)
The current stock price of CRDF is 2.39 USD. In the past month the price decreased by -41.28%. In the past year, price increased by 0.42%.
CRDF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.7 | 349.84B | ||
| AMGN | AMGEN INC | 13.22 | 154.98B | ||
| GILD | GILEAD SCIENCES INC | 15.43 | 148.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.64 | 94.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 60.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 57.23B | ||
| ARGX | ARGENX SE - ADR | 71.39 | 40.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.5 | 31.19B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.84B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.28B | ||
| INSM | INSMED INC | N/A | 20.78B | ||
| NTRA | NATERA INC | N/A | 20.75B |
Related stock screener links
About CRDF
Company Profile
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 32 full-time employees. The company went IPO on 2004-07-27. The company is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. The company is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. The company has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Company Info
CARDIFF ONCOLOGY INC
11055 Flintkote Ave
San Diego CALIFORNIA 92121 US
CEO: Mark Erlander
Employees: 33
Phone: 18589527570
CARDIFF ONCOLOGY INC / CRDF FAQ
What is the stock price of CARDIFF ONCOLOGY INC today?
The current stock price of CRDF is 2.39 USD. The price decreased by -0.83% in the last trading session.
What is the ticker symbol for CARDIFF ONCOLOGY INC stock?
The exchange symbol of CARDIFF ONCOLOGY INC is CRDF and it is listed on the Nasdaq exchange.
On which exchange is CRDF stock listed?
CRDF stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CARDIFF ONCOLOGY INC stock?
14 analysts have analysed CRDF and the average price target is 11.99 USD. This implies a price increase of 401.46% is expected in the next year compared to the current price of 2.39. Check the CARDIFF ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CARDIFF ONCOLOGY INC worth?
CARDIFF ONCOLOGY INC (CRDF) has a market capitalization of 159.01M USD. This makes CRDF a Micro Cap stock.
How many employees does CARDIFF ONCOLOGY INC have?
CARDIFF ONCOLOGY INC (CRDF) currently has 33 employees.
What are the support and resistance levels for CARDIFF ONCOLOGY INC (CRDF) stock?
CARDIFF ONCOLOGY INC (CRDF) has a support level at 2.38 and a resistance level at 4.2. Check the full technical report for a detailed analysis of CRDF support and resistance levels.
Is CARDIFF ONCOLOGY INC (CRDF) expected to grow?
The Revenue of CARDIFF ONCOLOGY INC (CRDF) is expected to decline by -32.46% in the next year. Check the estimates tab for more information on the CRDF EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CARDIFF ONCOLOGY INC (CRDF) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRDF, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRDF, evaluating the profitability, health, valuation and growth aspects
- CARDIFF ONCOLOGY INC (CRDF) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CARDIFF ONCOLOGY INC (CRDF) Sales and EPS estimates to see what analysts future expectations are.
- CARDIFF ONCOLOGY INC (CRDF) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CARDIFF ONCOLOGY INC (CRDF) Insider and Institutional Ownership to learn about the owners and their transactions.
- CARDIFF ONCOLOGY INC (CRDF) Stock Chart to make your own analysis
- CARDIFF ONCOLOGY INC (CRDF) Latest news and press-releases to stay up to date.
Does CARDIFF ONCOLOGY INC (CRDF) stock pay dividends?
CRDF does not pay a dividend.
When does CARDIFF ONCOLOGY INC (CRDF) report earnings?
CARDIFF ONCOLOGY INC (CRDF) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of CARDIFF ONCOLOGY INC (CRDF)?
CARDIFF ONCOLOGY INC (CRDF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).
What is the Short Interest ratio of CARDIFF ONCOLOGY INC (CRDF) stock?
The outstanding short interest for CARDIFF ONCOLOGY INC (CRDF) is 30.38% of its float. Check the ownership tab for more information on the CRDF short interest.
CRDF Technical Analysis
CRDF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRDF. While CRDF seems to be doing ok healthwise, there are quite some concerns on its profitability.
CRDF Financial Highlights
Over the last trailing twelve months CRDF reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 3.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.39% | ||
| ROE | -87.1% | ||
| Debt/Equity | 0 |
CRDF Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CRDF. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 14.64% and a revenue growth -32.46% for CRDF